An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate
Author:
Affiliation:
1. Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland
2. Department of Public Health and Preventive Medicine, Oregon Health & Science University, Portland
Publisher
American Medical Association (AMA)
Subject
Internal Medicine
Link
http:///jamainternalmedicine/article-pdf/179/7/915/17690761/jamainternal_chen_2019_oi_190022.pdf
Reference28 articles.
1. The FDA’s expedited programs and clinical development times for novel therapeutics, 2012-2016.;Hwang;JAMA,2017
2. Endpoints for assessing drug activity in clinical trials.;Pazdur;Oncologist,2008
3. Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses.;Blumenthal;J Clin Oncol,2015
4. Oncology drug approvals: evaluating endpoints and evidence in an era of breakthrough therapies.;Blumenthal;Oncologist,2017
5. A 25-year experience of US Food and Drug Administration accelerated approval of malignant hematology and oncology drugs and biologics: a review.;Beaver;JAMA Oncol,2018
Cited by 114 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Surrogate endpoints in phase III randomized trials of advanced gastroesophageal cancer: A systematic review and meta-analysis;Critical Reviews in Oncology/Hematology;2024-09
2. What clinicians should know about surrogate end points in hematologic malignancies;Blood;2024-07-04
3. Regulatory histories of recently withdrawn ovarian cancer treatment indications of 3 PARP inhibitors in the US and Europe: lessons for the accelerated approval pathway;Journal of Pharmaceutical Policy and Practice;2024-06-04
4. Overall survival benefits of cancer drugs initially approved by the US Food and Drug Administration on the basis of immature survival data: a retrospective analysis;The Lancet Oncology;2024-06
5. Improvement of assessment in surrogate endpoint and safety outcome of single-arm trials for anticancer drugs;Expert Review of Clinical Pharmacology;2024-04-21
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3